The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 19, 2026

Filed:

Nov. 01, 2019
Applicant:

Northwestern University, Evanston, IL (US);

Inventors:

Peng Ji, Wilmette, IL (US);

Gary E. Schiltz, Naperville, IL (US);

Rama K. Mishra, Chicago, IL (US);

Atul D. Jain, Chicago, IL (US);

Assignee:

Northwestern University, Evanston, IL (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 403/06 (2006.01); A61K 47/54 (2017.01); A61K 47/55 (2017.01); A61P 35/00 (2006.01); C07D 409/14 (2006.01);
U.S. Cl.
CPC ...
A61K 47/55 (2017.08); A61K 47/54 (2017.08); A61P 35/00 (2018.01); C07D 403/06 (2013.01); C07D 409/14 (2013.01);
Abstract

Disclosed herein are compounds, compositions, and methods for treating cell proliferative diseases and disorders based on present inventors discovery that Pleckstrin-2 (Plek2) can be targeted to treat cell proliferative diseases and disorders. The compositions and methods disclosed herein include or utilize the disclosed compounds as therapeutic agents which inhibit the biological activity or expression of Pleckstrin-2 (Plek2) and collectively may be referred to as 'Plek2 inhibitors.' Disclosed are small molecule inhibitors of Plek2 biological activity. The compositions and method may be utilized for treating cell proliferative diseases and disorders that are characterized by elevated levels of Plek2 expression and/or by activation of the phosphatidylinositide 3-kinase (PI3K)/Akt pathway. Cell proliferative diseases and disorders that may be treated using the disclosed compositions and methods may include, but not limited to, myeloproliferative neoplasms (MPNs) such as Philadelphia (Ph)-negative MPNs, and cancers such as acute myeloid leukemia (AML) and cancers characterized by solid tumors.


Find Patent Forward Citations

Loading…